CNS Pharmaceuticals Launches Strategy to Build Neurology and Oncology Drug Pipeline
Houston, Texas, United States — March 11, 2026 Biotechnology company CNS Pharmaceuticals has announced the launch of a new...
Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
Houston, Texas, United States — March 11, 2026 Biotechnology company CNS Pharmaceuticals has announced the launch of a new...
New York, United States — March 10, 2026 Biotechnology company Dianthus Therapeutics has announced the pricing of an upsized...
New York, United States & Waltham, Massachusetts – March 9, 2026 Dianthus Therapeutics, Inc., a clinical-stage biotechnology company focused...
